Aerovate Therapeutics, Inc. (AVTE)

NASDAQ: AVTE · IEX Real-Time Price · USD
0.39 (3.05%)
May 20, 2022 4:00 PM EDT - Market closed

Company Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States.

The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.

Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Aerovate Therapeutics, Inc.
CountryUnited States
IPO DateJun 30, 2021
SectorHealth Care

Contact Details

930 Winter Street
Waltham, MA 02116
United States
Phone617 443 2400

Stock Details

Ticker SymbolAVTE
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$14.00
CIK Code1798749

Key Executives

Timothy P. Noyes M.B.A.Chief Executive Officer and Director
Dr. Benjamin T. Dake Ph.D.Founder, President, Chief Operating Officer and Secretary
George A. EldridgeChief Financial Officer and Treasurer
Hunter Gillies M.D.Chief Medical Officer
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.SChief Development Officer
Timothy J. PigotSenior Vice President of Commercial
Donna DeaHead of Regulatory Affairs
Dr. Marinus Verwijs Ph.D.Senior Vice President of CMC
Sue FischerSenior Vice President of Development Operations

Latest SEC Filings

May 16, 202210-QQuarterly report [Sections 13 or 15(d)]
May 16, 20228-KCurrent report
May 5, 2022SC 13D/AGeneral statement of acquisition of beneficial ownership
Apr 29, 2022DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2022DEF 14AOther definitive proxy statements
Apr 29, 20228-KCurrent report
Apr 4, 20224Statement of changes in beneficial ownership of securities
Mar 30, 2022S-8Securities to be offered to employees in employee benefit plans
Mar 30, 202210-KAnnual report [Section 13 and 15(d), not S-K Item 405]
Mar 30, 20228-KCurrent report
View All SEC Filings